Understanding Mootraghata In Ayurveda With Special Reference To Benign Prostatic Hyperplasia: A Conceptual Review
Abstract
Benign Prostatic Hyperplasia (BPH) represents a significant global health challenge, characterized by lower urinary tract symptoms (LUTS) that impact the quality of life for aging men. In parallel, Ayurvedic medicine describes a spectrum of urinary disorders under the umbrella term Mootraghata, which shares considerable symptomatic and pathophysiological commonalities with BPH. This conceptual review aims to bridge the understanding between these two medical paradigms, exploring their parallels in etiology, pathogenesis, clinical features, and therapeutic strategies. The analysis reveals that Mootraghata functions as a broad syndrome encompassing various urinary pathologies, with specific subtypes like Vatashteela demonstrating a close resemblance to BPH. Central to Ayurvedic understanding is the vitiation of Apana Vayu and the suppression of natural urges (vegavarodha), which offer a unique, holistic perspective on the dynamic component of bladder outlet obstruction. Furthermore, the involvement of Kapha and Meda Dhatu aligns with the static component of prostatic enlargement. Traditional Ayurvedic therapies, particularly Basti Karma (including Matra Basti and Uttarbasti) and specific herbal formulations like Varuna, Shilajit, Kanchanara Guggulu, and Gokshura, are discussed for their potential to address BPH-like symptoms by balancing Doshas and supporting urogenital health. This review underscores the potential for an integrative approach, leveraging the strengths of both…
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.